3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Small Cell Lung Carcinoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplasms by Histologic Type
1
Neoplasms
1
Myeloproliferative Disorders
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid
1
Leukemia
1
Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
1
Hematologic Diseases
1
Endometrial Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Bone Marrow Diseases
1
Abiraterone Acetate
1
Interventions
pirtobrutinib
5
Lenalidomide
4
Rituximab
3
Imatinib Mesylate
3
ruxolitinib
2
ponatinib
2
ibrutinib
2
Platelet Transfusion
2
Brentuximab Vedotin
2
Bortezomib
2
Bendamustine Hydrochloride
2
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
zanubrutinib
1
vosaroxin
1
venetoclax
1
nilotinib
1
idelalisib
1
bosutinib
1
acalabrutinib
1
Zoledronic Acid
1
Vorinostat
1
Vincristine
1
Tretinoin
1
Prednisone
1
Plasma Exchange
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Exercise
1
Doxorubicin
1
Dexamethasone
1
Denosumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Hematologic Diseases
×
BID protein, human
×
Clear all
NCT02627677
2021-11-26
OPTIC-2L
Takeda
Phase 3
Terminated
44 enrolled
22 charts